Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Surgery Recovery Program Slashes Opioid Use, Benefits Patients, Cuts Costs

By University Of Virginia Health System | April 24, 2018

The University of Virginia Medical Center in Charlottesville, Va., has designed and implemented a thoracic surgery recovery program that benefits patients while reducing opioids and cutting costs, a new study shows.

A special recovery program for thoracic surgery patients developed and implemented at the University of Virginia Health System is getting patients home sooner while decreasing both healthcare costs and opioid use, a review of the first year of the program shows.

According to the new review, the program:

  • Reduced the use of morphine equivalents by 74 percent for one group of patients and 59 percent for another – without compromising patients’ evaluation of their pain levels;
  • Reduced the median length of hospital stay among thoracotomy (chest surgery) patients by two full days;
  • Saved more than $1.3 million while freeing up beds for an estimated 28 additional patients.

“Our goal is to guide our patients through their surgical journey as quickly and safely as possible and return them to normal activity as soon as possible,” said Linda W. Martin, MD, the program’s lead surgeon. “Engaging and educating patients about what to expect at each step of their chest operation, involving them in the recovery process, in conjunction with multiple changes in how doctors and nurses manage their medical needs at every step, has shortened the time they need to spend in the hospital.”

She noted the value the program has in preventing opioid addiction: “Pain control is of the highest priority for our enhanced recovery program, and with new combinations of medications we were able to achieve this with much less opioid medication,” Martin said. “This is good for patients in many ways – it exposes them to fewer side effects and risks and reduces their need for medicines that have addictive potential. An enhanced recovery program is a positive step towards helping with the opioid epidemic.”

About ERAS

UVA launched its thoracic Enhanced Recovery After Surgery (ERAS) program in early 2016. The multidisciplinary effort aimed to make thoracic surgery less stressful for patients and improve their care throughout the entire process.

The program enrolled 139 patients in its first year. To evaluate its success, program organizers compared patients’ outcomes and experiences to those of more than 220 previous patients who were not enrolled in the recovery program.

The review revealed the program had many benefits without increasing the rates of surgical complications or hospital readmission. The program organizers hope it will eventually reduce readmission rates as well.

“While it is difficult to assign cause and effect to any specific intervention, thoracic ERAS was clearly associated with substantial improvements in clinically relevant outcomes,” they conclude in the new review paper.

Improving Thoracic Surgery Care

The researchers note that there were several limitations to their review, including that their cost data did not go into fine detail. However, they pronounced the initiative a major success.

“I think that the major take-home point from our enhanced recovery program is that standardizing care for thoracic surgical patients in a way that incorporates preoperative patient preparation, nutritional optimization, avoidance of excessive intravenous fluids, and aggressive pain prevention while minimizing the need for opioids has the potential to dramatically improve care and lower hospital costs,” said Randal S. Blank, MD, PhD, the program’s lead anesthesiologist.

The researchers plan to continue to evaluate and improve the program by further monitoring patient outcomes and outpatient opioid use, among other factors.

The thoracic ERAS program is one of several surgical recovery programs UVA has implemented in its efforts to provide exceptional care. ERAS was originally introduced as a trial for patients undergoing elective colorectal surgery but proved so effective that UVA quickly broadened it to other areas, including gynecologic surgery and orthopedic surgery.

The patient-centered approach includes customized pain-management plans and efforts to get patients on their feet sooner, all with the intent of helping them heal and resume their normal lives more quickly.

As the thoracic surgery providers note in their paper, “The goal is to help the patient feel like a ‘person’ rather than a ‘patient’ as soon as possible.”

Findings Published

The findings have been published in the Annals of Thoracic Surgery. The paper’s authors were Martin, Bethany Sarosiek, Meredith Harrison, Traci Hedrick, James Isbell, Alexander Krupnick, Christine Lau, Hunter Mehaffey, Robert Thiele, Dustin Walters and Blank.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE